Drug Type Universal CAR-T |
Synonyms Anti CD19 universal chimeric antigen receptor T cell therapy(Shanghai Bioray Laboratory), CD19UCART, 靶向CD19基因修饰的异体嵌合抗原受体T细胞(上海邦耀) + [2] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 1 | - | 19 May 2022 | |
Acute Lymphoblastic Leukemia | Phase 1 | - | 19 May 2022 | |
Non-Hodgkin Lymphoma | Phase 1 | - | 19 May 2022 | |
Non-Hodgkin Lymphoma | Phase 1 | - | 19 May 2022 | |
Pre B-cell acute lymphoblastic leukemia | IND Approval | CN | 27 Jul 2023 | |
Autoimmune Diseases | Preclinical | CN | 30 Jan 2022 |